menu
    • menu
    [{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Lantheus Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holdings"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ POINT Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ POINT Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"177Lu-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals for Lutetium (177Lu) Zadavotide Guraxetan

    Menu

    Lutetium (177Lu) Zadavotide Guraxetan

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Eli Lilly

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Completes Acquisition of POINT Biopharma

                            Details : Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostat...

                            Brand Name : PNT2002

                            Molecule Type : Small molecule

                            Upfront Cash : $1,400.0 million

                            December 27, 2023

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Eli Lilly

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Eli Lilly

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

                            Details : Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostat...

                            Brand Name : PNT2002

                            Molecule Type : Small molecule

                            Upfront Cash : $1,400.0 million

                            October 03, 2023

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Eli Lilly

                            Deal Size : $1,400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Isotope Technologies Munich

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

                            Details : The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prosta...

                            Brand Name : PNT2002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Lantheus Holding

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of...

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 24, 2023

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Lantheus Holding

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 12, 2023

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Lantheus Holdings

                            Deal Size : $2,115.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            POINT Biopharma Announces Closing of Agreements with Lantheus Holdings

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : $260.0 million

                            December 20, 2022

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Lantheus Holdings

                            Deal Size : $2,115.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Lantheus Holding

                            Deal Size : $2,115.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commerc...

                            Details : Lu-177-PSMA-I&T (Lu-177-PNT2002) is a PSMA-Targeted therapy for mCRPC. PSMA is overexpressed in the vast majority of prostate cancers, but very limited to normal tissues. PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisot...

                            Brand Name : 177Lu-PSMA-I&T

                            Molecule Type : Large molecule

                            Upfront Cash : $260.0 million

                            November 14, 2022

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Lantheus Holding

                            Deal Size : $2,115.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : $13.9 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

                            Details : POINT intends to use the net proceeds from the proposed offering, to fund clinical and preclinical research and development programs including PNT2002 (Lu-177-PSMA-I&T), pre-commercialization activities, and for working capital and other general corporat...

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 16, 2022

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : $13.9 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            POINT Biopharma Prices Public Offering of Common Stock

                            Details : POINT intends to use the net proceeds from the proposed offering, to fund clinical and preclinical research and development programs including PNT2002, pre-commercialization activities, and for working capital and other general corporate purposes.

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 13, 2022

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial ...

                            Details : Key findings for PNT2002 (Lu-177-PSMA-I&T), include a median rPFS time of 11.5 months, along with a well-tolerated safety profile with no treatment-related deaths and few treatment-related AEs of grade 3 or higher.

                            Brand Name : PNT2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 09, 2022

                            Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth